Mirum Pharmaceuticals (MIRM) Completes Enrollment for Phase 3 EXPAND Study of LIVMARLI

Mirum Pharmaceuticals Inc. (NASDAQ:MIRM)  is one of the most promising stocks under $100 to buy. On March 16, Mirum Pharmaceuticals announced the completion of enrollment for its Phase 3 EXPAND study, which evaluates the efficacy and safety of LIVMARLI (maralixibat) in treating cholestatic pruritus. This randomized, double-blind, placebo-controlled trial focuses on patients aged 6 months and older who suffer from rare cholestatic liver diseases, such as biliary atresia.

The company aims to use this study to support a potential label expansion, addressing the debilitating itch and limited treatment options currently available for these specific conditions. The study specifically targets the impaired bile flow and elevated serum bile acids that lead to severe pruritus and a significantly reduced quality of life for affected families.

LIVMARLI is currently approved in the US and EU for pruritus associated with Alagille syndrome and progressive familial intrahepatic cholestasis, but the EXPAND study represents a critical milestone in reaching a broader patient population. Leadership from Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) and experts in pediatric medicine emphasized that for many of these rare conditions, there are still no approved targeted therapies for relentless itching. Topline data from the study is expected to be released in Q4 2026.

Photo by RephiLe water on Unsplash

Mirum Pharmaceuticals Inc. (NASDAQ:MIRM) is a biotech company that develops and commercializes novel therapies for rare & orphan diseases. The company’s lead product candidate, LIVMARLI (maralixibat), treats cholestatic pruritus in patients with Alagille syndrome.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.